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SUMMARY
The process of protein folding is remarkably efficient, but sometimes it can go
wrong. This can have harmful consequences, as the incorrect folding of proteins is
thought to be the cause of diseases.  Amyotrophic lateral sclerosis 8 (ALS8) caused by
the missense Thr46Ile and Pro56Ser mutation in the MSP domain of Vesicle-associated
membrane protein-associated protein B (VAPB)  is one example of such “ misfolding
diseases”, and also the main focus of my research. In this thesis, the first structural
investigation on both wild-type, Thr46Ile and Pro56Ser mutated MSP domains is
presented.
The results revealed that the wild-type MSP domain is well-folded at neutral pH
but can undergo acid-induced unfolding reversibly. It has thermodynamic stability energy
(G0N-U) of 7.40kcal/mol and is also active in binding to a Nir2 peptide with a Kd of
0.65μM. Further determination of its crystal structure reveals that it adopts a seven-
stranded immunoglobulin-like β sandwich.
By contrast, the Pro56Ser mutation renders the MSP domain to be insoluble in
buffer. Nevertheless, as facilitated by the discovery that “insoluble proteins” can be
solubilized in salt-free water (Li et al., 2006), we have successfully characterized the
residue-specific conformation of the Pro56Ser mutant by CD and heteronuclear NMR
spectroscopy. Surprisingly, the Pro56Ser mutant remains highly-unstructured under
various conditions, lacking of tight tertiary packing and well-formed secondary structure,
only with non-native helical conformation weakly-populated over the sequence. As such,
the abolishment of native MSP structure consequently leads to aggregation and loss of
functions under the physiological condition.
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Unexpectedly, unlike the Pro56Ser MSP domain mutant, the Thr46Ile mutation
did not eliminate the native secondary and tertiary structures, as demonstrated by its far-
UV CD spectrum, as well as Cα and Cβ NMR chemical shifts. However, the Thr46Ile
mutation did result in a reduced thermodynamic stability and loss of the cooperative urea-
unfolding transition which consequently causes it to be prone to aggregation at high
protein concentrations and temperatures in vitro. The same mutation also causes a 3 fold
reduction in its ability to bind to the Nir2 peptide and significantly eliminate its ability to
bind to EphA4. We have also provided evidence that the EphA4 and Nir2 peptide appear
to have overlapped binding interfaces on the MSP domain, which strongly implies that
two signalling networks may have a functional interplay in vivo.
Our study provides the first molecular basis for understanding the Pro56Ser and
Thr46Ile ALS-causing mutations. We have also shown that by introducing additional
Proline residues in the right context, the MSP domain could gain resistant to the Pro56Ser
mutation. Lastly, we hypothesized that the interplay of two signalling networks mediated
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2Proteins are polymers of amino acids. There are 20 different types of amino acids,
and by controlling the order and the number in which they are assembled into a
polypeptide chain, a vast array of different macromolecules can be efficiently constructed
by a single type of factory in the cell, the ribosome, using information encoded within the
DNA. In order to function, however, the synthesized polypeptide chain must fold into the
three-dimensional shapes that are critical to their function, their native conformation.
While it might take an eternity for the protein to explore the huge number of accessible
conformations before finding the native state (Levinthal, 1968), most of the time, proteins
can spontaneously seek out their native conformation (Anfinsen, 1973). Sometimes
folding is also assisted or even made possible by cellular enzyme complexes called
chaparones which protects the protein while it is folding. However, certain circumstances
can also cause proteins to misfold or unfold leading to various diseases.
1.1 Protein folding diseases
As mentioned, proteins need its fold to be functional. So unsurprisingly diseases
exist due to the inability of proteins to adopt, or remain in, it’s native functional
conformational state. Protein folding diseases can be divided into two groups: in the first,
a small error in the genetic blueprint leads to incomplete folding of a protein, which
affects its physiological function. This might, for instance, happen to p53, the
malfunctioning of this central tumor suppressor could cause cancer. In the other,
excessive quantities of wrongly folded or unfolded proteins aggregates, leading to
proteinaceous deposits that are pathogenic features of the disease. Systems such as the
unfolded protein response (UPR) and ubiquitin-proteasome complex are in place in the
cell to target misfolded proteins for degradation and clearance. However these systems
3maybe overwhelmed in the diseased state and the misfolded proteins accumulate as either
extracellular deposits (eg. senile plaques in Alzheimer's disease) or intracellular
inclusions (eg. Lewy bodies in Parkinson's disease). These deposits may be the direct
cause of the particular pathology associated with the diseases or they may be inert
"packages" designed to protect the cell from toxic insult.
In this thesis, I focused on two point mutations in the MSP domain of VAPB that
result in a form of protein folding disease that are characterized by the specific death of
nerves cells that control muscles. Several biophysical methods such as NMR, ITC and
CD was routinely used to investigate the structural characteristics of the wild type MSP
domain of VAPB and the assessment of the consequences of several key mutations. It is
hope that the knowledge provided in this thesis would contribute to the understanding of
the molecular mechanism underlying the mutation-causing disease.
1.2 What is Amyotrophic lateral sclerosis?
Amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease, motor
neuron disease (MND) or Charcot’s disease was first described by French neurologist
Jean-Martin Charcot in 1869 (Meininger, 2011). It is the most common adult-onset motor
neuron neurodegenerative disease characterized by the selective dysfunction and death of
upper and lower motor neurons projecting from the brainstem, spinal cord, corticospinal
tracts and primary motor cortex (Nassif et al., 2010). This lethal, progressive disorder
causes patients to suffer from a spectrum of symptoms which includes muscle weakness,
atrophy, paralysis and bulbar symptoms which eventually leads to death due to
respiratory muscle failure.
1.2.1 Disease forms – Sporadic and Familiar ALS
4ALS is divided into two forms, sporadic ALS (SALS) and familiar ALS (FALS).
SALS constitute the majority of ALS cases and the disease occurs apparently at random
with no clear associated risk factors. FALS patients on the other hand, carry an
inheritable pathogenic gene mutation and make up 5 to 10% of the diseased population.
1.2.2 Genetic risk factors
Despite the difference in genetic components, both SALS and FALS cases are
clinically indistinguishable and share the same pathological features (Chen et al., 2010).
It is therefore thought that knowledge gained from studying the pathogenic genes
identified in FALS patients may eventually elucidate the potential mechanisms that lead
to the death of motor neurons in ALS and provide insights for an efficient treatment for
both disease forms (Bruijn et al., 2004 and Pasinelli et al., 2006). To date, multiple genes
that are causative or closely linked to the onset of FALS have been identified through
genetic screening of FALS kindred. These genes include: ang on chromosome
(Greenway et al., 2004 and Greenway et al., 2006), sod1 on chromosome 2 (Rosen et al.,
1993 and Shaw, 2005), als2 on chromosome 2 (Hadano et al., 2001; Yang et al., 2001
Hadano et al., 2006), setx on chromosome 9 (Chen et al., 2004), fus on chromosome 16
(Kwiatkowski et al., 2009 and Vance et al., 2009), vapb on chromosome 20 (Nishimura
et al., 2010; Chen et al., 2010 and Hamamoto et al., 2005), tardbp on chromosome 1
(Yokoseki et al., 2008; Sreedharan et al., 2008 and Kabashi et al., 2008), chmp2b on
chromosome 3 (Momeni et al., 2006 and Parkinson et al., 2006) and dctn1 on
chromosome 2 (Puls et al., 2003 and Munch et al., 2004) which encodes for
Angiogenin, Cu/Zn superoxide dismutase 1, Alsin, Senataxin, Fused in sarcoma protein
(FUS), VAMP (vesicle-associated membrane protein)-associated protein B (VAPB), TAR
5DNA binding protein 43 (TDP-43), charged multi-vesicular body protein 2b, and
dynactin 1 respectively (table 1).
1.2.3 Environment risk factors
Although several genetic risk factors have been identified to cause FALS, the cause
of SALS remains largely unknown. Numerous researches have also focused on studying
various aspects of our lifestyle that could possibly interact with genes to cause or
contribute to SALS. A large number of environment risk factors have been studied in
recent years and to name a few, these includes: exposure to agricultural chemicals or
contact with animals linked to agricultural work (Furby et al., 2010); pesticide exposure
(Sutedja et al., 2009) and smoking (Armon, 2009). However, there is still insufficient
evidence to implicate any environment risk factor as being responsible for the cause of
SALS.
1.3 The human VAP (hVAP) family of proteins
The Vesicle-associated membrane protein (VAMP)-associated protein (VAP)
family were initially identified as orthologues of VAP-33, a 33Kda protein in Aplysia
californica through its ability to bind to the vesicle - soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (v-SNARE), VAMP1 and VAMP2, in a yeast two-
hybrid screen (Skehel et al., 1995). The VAP family of proteins is highly conserved
among Eukaryotics. Humans have two VAPs (hVAPs), VAPA and VAPB (Nishimura et
al., 1999) and share ~60% sequence identity. Alternatively spliced variants of the VAPB
gene exists and lacked specific exons of VAPB, i.e. exon 2 (VAPB-2), exons 4 and 5
(VAPB-4, 5), exon 3 (VAPB-3), and exons 3 and 4 (VAPB-3, 4) and exons 3 to 5 VAPC
(Nishimura et al., 1999 and Nachreiner et al,., 2010).
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71.3.1 Expression and subcellular localization
VAPA and VAPB are ubiquitously expressed in various mammalian tissues and
organs (Weir et al., 1998; Nishimura et al., 1999 and Skehel et al., 2000), including the
heart, placenta, lung, liver, skeletal muscle, and pancreas. Both hVAPs are also found in a
wide range of intracellular membranes, including the Endoplasmic reticulum (ER)
(Skehel et al, 2000), the Golgi, the ER–Golgi intermediate compartment (Soussan et al.,
1999), recycling endosomes, tight junctions (Lapierre et al., 1999), the neuromuscular
junctions (Pennetta et al., 2002), and the plasma membrane (Foster and Klip, 2000).
Because of this broad distribution, the hVAP family of proteins is suggested to be
involved in diverse cellular functions.
Other than VAPC, the expression of the alternative splice variants of the VAPB
gene has never been demonstrated in mammalian tissues or organs. They were, however,
detected by Nachreiner et al., (2010) only at the mRNA level in various tissues of the
nervous system such as the muscle, cerebellum, cortex and spinal cord. In vitro, two of
the variants (VAPB-2 and VAPB-4, 5) were detectable on the protein level in transfected
over expressing 293 cells. Two other variants (VAPB-3 and VAPB-3, 4) became
detectable only after inhibition of the ubiquitin/proteasomal pathway, a condition
commonly found in neurodegenerative diseases such as Alzheimer’s disease and
Parkinson’s disease (Hoozemans et al., 2006). The expression of VAPB-2, 3, 4 was never
detected in vitro. It was then hypothesized that these splice variants of VAPB might
become highly expressed under pathological conditions and contribute to ALS
pathogenicity as with other splice variants of ALS-associated proteins such as SOD1
(Hirano et al, 2000) or the glutamate transporter EAAT2 (Honig et al., 2000).
8The tissue distribution of VAPC remains largely unknown but kukihara et al.,
(2009) had shown through immunoblotting of pool lysates of various organs prepared
from several people that several bands detected by Anti-VAPC antibody despite being
smaller than the expected size of VAPC were observed in the stomach, duodenum, small
intestine, uterus, vagina, prostate, and bladder. However, VAPC was not detected in liver
tissues in which the Hepatitis C Virus replicates.
1.3.2 Domains of hVAPs
The hVAP proteins are composed of three conserved domains, namely an N-
terminal Major Sperm Protein (MSP) domain, a central coiled-coil domain, and a C-
terminal transmembrane (TM) domain (Figure 1a).
1.3.2.1 The MSP domain
The hVAPs possess an amino (N)-terminal, cytoplasmic facing domain of about
125 residues. It was named the MSP domain because of its similarity (22% sequence
identity) with the nematode major sperm protein (MSP), a protein that mediates the
amoeba-like crawling motion in nematode sperms by forming an extensive fibrous
network at the leading edge of the sperm’s pseudopod. The MSP and VAP MSP domain
share an evolutionary conserved immunoglobulin-like seven-stranded β sheet domain
fold (Baker et al., 2002 and Kaiser et al., 2005) but unlike VAPs, the MSP does not
contain a coiled-coil motif or a transmembrane domain. Thus, the VAP MSP domain, like
the MSP may function to facilitate the oligomerisation of VAPs. Indeed, Haaf et al.,
(1998) had demonstrated that the MSP dimerizes spontaneously in solution. In vivo, the
MSP dimer form helical long chains which further associate with each other to form
filaments, which in turn forms supercoils to produce bundles. But contrary to the
9proposed function of VAPs MSP domain, the isolated VAPA MSP domain remains
monomeric (Kaiser et al., 2005). Kim et al., (2010) also further provided clear evidences
that the MSP domain of VAPB does not contribute to VAPB oligomerisation.
The hVAP MSP domain also harbors a particularly conserved 16 amino acid
segment – the VAP consensus sequence (VCS) (Nishimura at al., 1999) (figure 1b). It is
also interesting to note that while most VAPs have three prolines within the VCS, VAPB
and a nematode VAP, VPR-1, have only two prolines in this region. The distribution of
the Proline residues in the VCS as proposed by Nakamichi et al., (2011) is critical for the
proper MSP structure, and hence any alterations will affect the cellular localization,
substrate specificity and ultimately the function of VAPs. The Pro56Ser mutation on
VAPB which causes ALS8 leaves only a single Proline residue within the VCS. Based on
this hypothesis, Nakamichi et al., (2011) further showed that when Scs2p and VAPA were
mutated to be similar to VAPB (P56S) leaving only a single Proline in the VCS region,
Scs2p became inactive and aggregated, and VAPA became localized to membranous
aggregates indistinguishable from those induced by VAPB (P56S). However contrary to
the believe that the inclusion of an additional Proline at position 63 of VAPB will render
it resistance to the Pro56Ser alike VAPA (P56S), the localization of VAPB (P56S, A63P)
was similar to that of VAPB (P56S) and different from that of VAPA (P56S). Henceforth,
this suggests that another factor(s) other than the distribution or three Proline residues in
the VCS is required for proper cellular localization of VAPB.
Interestingly, the VCS was lacking in the splice variants VAPB-2 and VAPB-2,3,4
due to the loss of exon 2. The other spice variants VAPC, VAPB-3, VAPB-3,4 and VAPB-
4,5 on the other hand contain the Pro56 residue that is mutated to a Serine residue in
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ALS8 patients despite having a reorganized MSP domain. This thus indicates a relevance
of these splice variants to ALS8 as they can also contribute to pathogenesis due to the
inability to interact with FFAT-motif containing protein or because of the pathogenic
P56S mutation.
1.3.2.2 The coiled coil domain
The hVAPs also possesses a variable central coiled coil domain (CCD) of ~50
amino acids that resembles the CCD repertoire found in VAMPs and other SNARE
proteins (Nishimura et al., 1999). By using chemical cross-linking and co-
immunoprecipitation experiments, Kim et al., (2010) had shown that the deletion of the
CCD domain from the wild type VAPB abolished dimerization of VAPB without
affecting its ability to interact with the FFAT motif-containing protein Nir2. This has
provided clear evidences that CCD is critical for VAPB oligomerisation.
1.3.2.3 The TM domain
Finally, the hVAPs possess a single carboxyl (C)-terminal hydrophobic stretch
which anchors the hVAPs to the Endoplasmic reticulum (ER) membrane. This membrane
topology defines the VAPs as C-tail-anchored (C-TA) protein (Borgese et al, 2007). As
seen in figure 1c, the TM domain (TMD) contains a GXXXG motif and is recognized as
a “dimerization motif,” which mediates the assembly of two TM helices (Brosig et al,
1998; Russ et al, 2000 and Senes et al, 2004). Indeed, Nishimura, et al (1999) had
demonstrated that the VAPB undergoes homo- dimerization with itself and also hetero-
dimerization with VAPA, VAMP1 and VAMP2 through the TM domain. In another study,
Kim et al., (2010) further showed that by replacing the two glycines in the “dimerization
motif” with isoleucine, the dimerization of TM helices is abolished but has no effect on
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the oligomerization of full length VAPB. Henceforth, the GXXXG motif contributes only
to the oligomerisation of the TM domain but not of the full length protein.
1.3.3 Cellular functions of hVAPs
The VAPs interacts with a plethora of other proteins and their known interactors are
summarized in Table 2 (taken and modified from (Lev et al., 2008). The array of
interactions is diverse and broad, henceforth in this chapter; I will focus only on the
cellular functions of hVAPs that might have a relation to ALS pathogenesis.
1.3.3.1 Interactions with FFAT-motif containing proteins.
The hVAP proteins have been shown to interact with proteins carrying a short motif
consisting of two phenylalanines in an acidic tract (Wyles et al., 2002, Wyles and
Ridgway, 2004). This short motif is termed the FFAT motif and corresponds to the
consensus sequence EFFDAxE. Through the FFAT motif, hVAPs interact with a
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multitude of lipid-binding, lipid sensing or lipid-transport proteins (Table 2) and mediates
the transfer of lipids between the ER and other organelles, such as the Golgi, endosomes,
and plasma membrane (Olkkonen, 2004; Holthuis and Levine, 2005; Levine and Loewen,
2006; Kawano et al., 2006; Perry and Ridgway, 2006). The hVAPs also interact with
intracellular proteins (Wyles et al., 2002 and Weir et al., 2001) including Nir1, Nir2, and
Nir3 via the FFAT motif which differentially affects the organization of the ER (Amarilio
et al., 2005). The hVAPs also interact with the ceramide transporter CERT via the FFAT
motif and target it to the Golgi apparatus (Hanada et al., 2007, Kawano et al., 2006).
CERT mediates the transport of Ceramide from the ER where it was synthesized to the
Golgi where it is being converted to sphingomyelin, a major component of cellular
membranes.
The FFAT motif interacts with VAPs via a highly conserved region in the N-
terminal MSP domain. Co-crystallization of rat VAPA MSP domain and rat ORP1
fragment containing the FFAT motif (EFYDALS) revealed a 2:2 complex (PDB ID:
1Z90) in which the FFAT motif binds to a positive surface of VAPA (Kaiser et al., 2005 ).
The crystal complex together with mutagenic screens (Loewen et al., 2005 and Kaiser et
al., 2005) on hVAPs revealed several key residues which are crucial for FFAT binding:
Lys45, Thr47, Lys87, Met89 and Lys118. Most recently, Furuita et al., (2010) also
revealed the NMR solution structure (PDB: 2RR3) of human VAPA MSP domain and a
FFAT motif (EFFDAPE) containing fragment of OSBP in a 1:1 complex.
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1.3.3.2 Involvement of VAPB in the Unfolded Protein Response
1.3.3.2.1 The Unfolded Protein Response (UPR)
The endoplasmic reticulum (ER) is a reticular membranous network throughout the
cytoplasm of eukaryotic cells in which proteins are synthesized and post-translationally
modified for proper folding and function. However, not all newly synthesized proteins
are folded correctly and the percentage of misfolded protein was estimated to be at 30%
in normal cells (Schubert et al., 2000). With the help of ER chaperones such as Binding
Ig protein (BiP), a fraction of these misfolded proteins are refolded to have correct
structures, whereas the rest remain misfolded and accumulate in the ER lumen. This
causes ER stress (Ellgaard et al., 1999) that alerted the ER-resident stress sensors which
transduce the signals from the ER lumen to trigger an adaptive self-defense response
called the unfolding protein response (UPR) to decrease the load of misfolded proteins. In
addition to the UPR, the ubiquitin–proteasome systems (Werner et al., 1996) also play a
role to reduce the stress on ER, by degrading misfolded proteins that are transported to
the cytosol via the translocon.
In mammals, there are three main types of ER-resident stress sensors, IRE1 (a
transmembrane serine/threonine kinase and an endoribonuclease), PERK (an ER-resident
type I transmembrane protein kinase) and ATF6 (an ER-localized leucine zipper
transcription factor) (Kohno 2007). Under the normal conditions, the ER luminal
domains of these sensor proteins and of the ER chaperone, BiP associates to keep the
sensor proteins inactive. Once ER stress occurs, BiP dissociates from the sensor proteins
to be engaged in refolding the accumulated misfolded protein. The sensor proteins are
then freed and are activated to initiate the UPR by regulating a number of pathways.
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After dissociation from BiP, free IRE1 oligomerize and autophosphorylate, which
results in its activation (Bertolotti et al., 2000). Under normal ER stress condition, the
activated IRE1 initiates splicing of XBP1 mRNA to generate an active XBP1 which work
as a transcription factor to upregulate the expression of ER chaperons such as BiP and
GRP94. The increased level of ER chaperone caused refolding (Harding et al., 2000) of
accumulated misfolded proteins in ER. Under a severe ER stress condition, the activated
IRE1 interacts with TRAF2 and activates an apoptosis-stimulating kinase 1 (ASK1)/c-jun
N-terminal kinase (JNK) cascade that triggers apoptosis (Urano et al., 2000).
PERK (PKR-like ER protein kinase) also oligomerize, autophosphorylate and
become activated after dissociation from BiP (Bertolotti et al., 2000). Activated PERK
phosphorylates and inactivates eukaryotic translation-initiation factor 2α (eIF2α) to
suppress global protein translation thereby reducing the load on the ER (Harding et al.,
1999). In addition, phosphorylated eIF2α also enhances translation of ATF4 (Harding et
al., 1999 and Vattem et al., 2004) which in turn upregulates the expression of key genes
important for recovery from ER stress. Under a severe ER stress condition, expression of
apoptosis-related transcription factor, CHOP (Zinszner et al., 1998) is also induced via
the PERK pathway.
Unlike IRE1 and PERK which autophosphorylates upon dissociation from BiP,
ATF6 (activating transcription factor 6) translocates to the Golgi apparatus and is cleaved
by site 1 protease (S1P) and site 2 protease (S2P). This result in the release of its
cytoplasmic basic leucine zipper (bZIP) domain from the membrane and its translocation
to the nucleus where it functions as a transcriptional factor to activate genes encoding
molecular chaperones and proteins involved in ER-associated degradation (Ye et al.,
16
2000).
Some cells are particularly sensitive to ER stress such as the neurons cells
(Oyadomari and Mori., 2004) which has a large cell body with slow/no turnover and
pancreatic β cells (Lipson et al., 2006) which are actively producing secretary proteins
and. Through these well-organized self-defense systems, cells try to escape from ER
stress. Unfortunately there is a limit to this homeostatic response and in several cellular
conditions such as an elevated demand for protein secretion (Lipson et al., 2006 and Gass
et al., 2002); presence of pathogenic missense mutations (Bartoszewski et al., 2008 and
Ito et al., 2009); viral infection (Isler et al., 2005) and deprivation of nutrient/oxygen
(Lee, 1992 and Feldman et al., 2005), protein misfolding are enhanced and/or UPR are
misregulated, resulting in an overwhelming ER stress that results in the fatal outcome of
cells.
1.3.3.2.2 VAPB is involved in the activation of UPR
Kanekura et al., (2006) had demonstrated that over expression of wild-type (wt)-
hVAPs (VAPA and VAPB) but not other synaptic vesicular proteins, VAMP1 or VAMP2
induces the IRE1-mediated XBP1 splicing reaction which activates UPR. Also, by
reducing the level of endogenous VAPB using small interfering RNA, the group provided
further evidences that activation of UPR due to ER stress caused by DTT or thapsigargin
can be attenuated. In addition, Suzuki et al., (2009) also showed that VAPB mutants
(K87D/M89D-VAPB and T46A/T47A-VAPB) that localize normally to the ER like wt-
VAPB but do not interact with FFAT motif-containing protein are unable to trigger UPR
as well. In another experiment, Suzuki et al., (2009) further showed that VAPB mutants
with a truncated MSP domain or a deleted TM domain were also unable to trigger UPR.
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Taken together, these observations have suggested that the MSP domain of wt-VAPB
with proper ER localization and maybe a FFAT motif-containing protein is
physiologically involved in activation of the IRE1/XBP1 signaling pathway. The
involvement of VAPB on UPR was also confirmed by Chen at al., (2010).
VAPB is also involved in the ATF6 dependent pathway of UPR by interacting
directly with the ER-localized transcription factor ATF6 via its cytosolic MSP domain.
But in contrast to the study by Kanekura et al., (2006) showing that VAPB is a positive
regulator of UPR, Gkogkas et al., (2008) in their studies established that over expression
of VAPB attenuates the activity of ATF6, and reducing VAPB levels enhance ATF6-
dependent transcription.
The involvement of VAPB in the PERK pathway of UPR was also investigated by
Chen at al., (2010). However, phosphorylation of eIF2α was not significantly enhanced
or reduced in cells over expressing VAPB.
In conclusion, the work by the three independent groups showed that VAPB could
influence UPR by acting through the IRE1/XBP1 or the ATF6 pathway. Henceforth the
effect of the ALS8 causing mutation – Pro56Ser and Thr46Ile on UPR is worthy of
attention.
1.3.3.3 Interactions with Eph receptors.
The erythropoietin-producing hepatocellular carcinoma (Eph) receptors are
transmembrane receptors tyrosine kinases that have been implicated in numerous cellular
functions such as cell signaling and development. In the human genome there are nine
EphA receptors, which promiscuously bind five glycosylphosphatidylinositol (GPI)
linked ephrin-A ligands; and five EphB receptors, which promiscuously bind three
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transmembrane ephrin-B ligands (Elena, 2010). Exceptions are the EphA4 and EphB2
receptors, which can also bind ephrin-Bs and ephrin-A5, respectively, and EphB4, which
preferentially binds ephrin-B2 only (Elena, 2010).
Multiple Ephrins and Eph receptors including EphA4 and A7 are can be found
throughout the adult nervous system and in skeletal muscle of vertebrate species
(Iwamasa et al., 1999 and Lai et al., 2001). Eph receptors are implicated in the regulation
of the survival of cultured spinal cord motor neurons (Magal et al., 1996) and influence
proliferation and apoptosis in the adult mammalian CNS (Ricard et al., 2006)).
Additionally, binding to Eph receptors expressed by neurons could stabilize synapses
(Calò et al., 2006). Thus, it is possible that Eph receptors signaling in expressing cell
might be crucial in mediating the susceptibility of motor neurons in ALS patients.
Indeed, in 2008, Tsuda et al., demonstrated that cleavage of the full length
drosophila VAP (dVAP) releases the N-terminal MSP domain which although lack an N-
terminal signal sequence, are secreted from cells by an as yet unidentified unconventional
mechanism (Kosinski et al., 2005). This finding is further supported by an earlier study
by Omenn et al., (2005) whom discovered the presence of hVAP MSP domain in the
blood serum using mass spectrometry. Tsuda et al., (2008) also showed that the hVAP
MSP domain is able to bind the extracellular ligand binding domain of EphA4 in a pull-
down assay; and also competes with mouse EphrinB2 for EphA4. Their work revealed a
testable novel pathway in which VAP fragments present in the blood serum may act as
diffusible hormones for Eph receptors present on neuron cells and may be crucial for
motor neuron survival or muscle functions.
1.4 ALS8-causing mutations in VAPB
19
A form of FALS classified as amyotrophic lateral sclerosis type 8 (ALS8) is caused
by a mis-sense point mutation in the MSP domain of hVAPs. This disease-associated
mutation first identified by Nishimura et al., (2004) substitutes a highly conserved
Proline residue at position 56 with a Serine (P56S) in the VCS of VAPB. The same
mutation was also identified in patients with different clinical courses, such as late-onset
spinal muscular atrophy (SMA), and typical severe ALS with rapid progression
(Nishimura et al 2005). Nevertheless, all of these neurodegenerative disorders are
characterized by the death of motor neurons. A second disease-associated mutation also
in the VCS of VAPB with similar effects substitutes a highly conserved Threonine residue
at position 46 with an Isoleucine (T46I) has also recently been reported by Chen et al.,
(2010). It is believed that the P56S and T46I mutations have the same effect in ALS
pathogenesis.
In 2008, two additional mutations in a non-conserved region of VAPB were also
reported (Landers et al., 2008): D130E (aspartic acid to glutamic acid at position 130)
and del160 (deletion of amino acid at position 160, which is a serine). However, the
D130E mutant were found to be in the same ratio between ALS patients and healthy
individuals by a study in southern Italy (Conforti et al., 2006) and therefore suggested
that it might not be an ALS causative gene. Also the del160 mutant was an isolated case
and is identified in only one individual of a family. Finally, both D130E and del160
mutants do not form cytoplasmic aggregates like the P56S and T46I mutant which further
suggests that if they are causative genes for ALS8, they might act via a mechanism which
may be distinctly different form P56S and T46I.
So far no diseases associated mutation has been identified in the VAPB
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homologue, VAPA. Also, it has been demonstrated experimentally that while the P56S
mutation dramatically influences the activity of VAPB, it does not have a significant
effect on VAPA.
1.4.1 Functional consequences of mutations
To elucidate the possible mechanism that leads to ALS8, several groups had
biochemically and biologically characterized ALS-linked VAPB (P56S), VAPA (P56S)
and recently VAPB (T46I) by Chen et al., (2010) and compared with wt-hVAPs, and have
found clear differences between them.
First of all, both VAPB (P56S) (Nishimura et al, 2004; Teuling et al, 2007 and
Kanekura et al, 2006) and VAPB (T46I) (Chen et al, 2010) formed large membranous
aggregates and causes ER structural change when expressed in cultured cells. In contrast,
wt-hVAP and VAPA (P56S) showed a reticulated subcellular distribution, colocalized
with ER. Both VAPB (P56S) and VAPB (T46I) mutants, unlike wt-hVAPs and VAPA
(P56S) are also resistant to solubilisation in buffers containing nonionic detergents such
as Triton X-100. In addition, the Triton X-100-insoluble VAPB mutants displayed a
smeared ladder mobility when analyzed with SDS-PAGE. These observations of VAPB
mutants together, suggested that P56S and T46I probably caused misfolding of wt-VAPB
and triggered VAPB protein aggregation (Kanekura et al, 2006 and Chen et al, 2010).
Another distinct difference between wt-VAPB and the VAPB mutants is the ability
to interact with FFAT motif-containing proteins. Using pull-down assays combined with
mass spectrometry, Teuling et al., (2007) had demonstrated that this interaction is
disrupted by the P56S mutation. The mechanism of which is elucidated by the work of
Kim et al., (2010) whom demonstrated that P56S obstructs FFAT binding through
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enhancing VAPB oligomerization and thus decreases accessibility to the VAPB binding
domain. The disruption of FFAT to VAP interaction causes a dysfunction in lipid
metabolism resulting in hyperlipidemia and increased cholesterol and triglyceride levels
in ALS8 patients (Marques et al., 2006 and Dupuis et al., 2008). These data together
suggest that VAPB (P56S) might manifest its pathogenicity because of its “loss of
function” mutation.
Overexpression of wt-hVAPs and related mutants also yielded different effects on
protein trafficking and further suggest that VAPB (P56S) might instead be a gain of
function mutant. In their study, Prosser et al., (2008) had experimentally shown that the
transport of membrane proteins from the ER to the Golgi is inhibited by over-expressed
wt-VAPA and VAPB (P56S) in CHO cells but not wt-VAPB. Additionally, they also
showed that such inhibition can be alleviated by over expressing FFAT containing
peptide. Intriguingly their studies also showed that the P56S aggregates could be
dissolved by FFAT overexpression. This however was contrary to another similar study
conducted by Teuling et al., (2007) which showed a lack of effect of FFAT containing
peptides to dissolve the membranous aggregates. This may reflect differences in the
FFAT constructs or the presence of a purification tag which might hinder interactions.
Indeed the construct used by Prosser et al., (2008) was a fragment from OSBP1 with a
small Myc tag at the N-terminus while Teuling et al., (2007) used a FFAT containing
fragment from Nir2 with a larger N-terminal GFP moiety. Since wt-VAPB has no effect
on protein trafficking, VAPB (P56S) is thought to gain a novel negative function which
could be rescued by the introduction of FFAT containing peptides.
In addition to such “loss or gain of function” phenotypes, VAPB (P56S) and VAPB
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(T46I) also have a unique dominant negative effect. To begin with, it was observed that
both VAPB (P56S) and VAPB (T46I) cause a redistribution of co-expressed wt-VAPB
from its normal localization and traps it into VAPB inclusions in mammalian cells and
Drosophila (Chai et al., 2008; Tsuda et al., 2008 and Chen et al., 2010) and prevent wt-
VAPB from fulfilling its role in any cellular function. Intriguingly, such co-aggregating
activity induced by the P56S mutation affects only VAPB but not VAPA and specifically
occurs only when P56S-VAPB is co-expressed with wt-VAPB, but not VAPA, VAMP1, or
VAMP2 (Kanekura et al. 2006). Later, Suzuki et al., (2009) further demonstrated that this
specific co-aggregating property of VAPB (P56S) is due to the development of an
aberrantly strong affinity for the MSP domain of wt-VAPB. In addition, the pathogenic
effect due to the mis-sense mutation in the MSP domain of VAPB is not limited to
cultured cells expressing them. In fact Chen et al., (2010) have shown that VAPB (T46I)
expressing cells have the ability to affect cells in an unclear mechanism that, although not
producing the mutant protein, they too become stressed and eventually undergo cell
death. Collectively, these observations support the hypothesis that VAPB (P56S)
specifically exerts a dominant-negative effect on co-expressed wt-VAPB or normal cells
expressing wt-VAPB.
Another striking difference observed by Chen et al., (2010) is that ubiquitinated
aggregates were abundant in both VAPB (P56S) and VAPB (T46I) expressing cells as
compared to wt-VAPB-expressing cells. The group further went on to investigate this
abnormality and discovered that the ubiquitin-proteasome system (UPS) was impaired by
an unknown mechanism in cells expressing VAPB (T46I). Again, untransfected cells co-
cultured with mutant VAPB transfected cells are also observed to be more likely to
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contain ubiquitinated aggregates than controls. The way damaged cells expressing a
pathogenic protein affect neighboring cells is intriguing and suggests that a non-cell-
autonomous mechanism may play a role in the pathogenesis of the disease (Ilieva et al,
2009).
Additional lines of evidences which suggested the presence of a non-cell-
autonomous mechanism at play comes from the work of Tsuda et al., (2008), Teuling et
al. (2007) and Mitne-Neto et al., (2011). First, Tsuda et al., (2008) proposed that the
P56S mutation inhibits the ability of the wt-VAPB MSP domain to be secreted and thus
prevented its interaction with Eph receptors. Reduced signaling due to VAP-Eph
interaction could also come from the down regulation of wt-VAPB expression. Indeed, it
is reported that the level of wt-VAPB is significantly reduced in the spinal cord of SOD1
mutants and SALS patient (Teuling et al., 2007) and also motor neurons derived from
induced pluripotent stem-cells of ALS8 patients (Mitne-Neto et al., (2011). It is therefore
possible that such reduced signaling may be responsible for some non-autonomous
defects leading to ALS pathogenesis. In contrast to the idea that MSP domain of wt-
VAPB is secreted from cells, Chen et al., (2010) was unsuccessful in recovering any
VAPB fragments from the culture medium. The group further suggests that wt-VAPB
may be released within exosomes, as has been shown for the secretion of α-synuclein
related to the pathology of Parkinson's disease (Emmanouilidou et al., 2010).
Finally, the ALS-associated T46I and P56S mutations in VAPB, also prevents wt-
VAPB from fulfilling its role in UPR. This was demonstrated by Kanekura et al., (2006)
and Chen at al., (2010) as they observed that the P56S and T46I mutations abolish the
ability of wt-VAPB to trigger UPR via the IRE1/XBP1 pathway. Their finding is
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consistent with the hypothesis that VAPB (P56S) and VAPB (T46I) is a loss-of-function
and dominant-negative mutant. On the contrary, Gkogkas et al., (2008) had proposed that
P56S-VAPB is instead a "toxic gain-of-function mutation. In his study, he has
demonstrated that VAPB (P56S) has an enhanced inhibitory activity towards ATF6-
dependent activation of UPR as compared to the wt-VAPB. Although further
investigations are required, the malfunctioning of UPR caused by VAPB (P56S) and
VAPB (T46I) is certainly worthy of attention.
In summary, we now have a plethora of knowledge about the pathogenic effects of
the ALS-associated VAPB mutations. Based on these results, several models of diseases
pathogenesis have been proposed and they can be broadly divided into three groups.
First, the ALS-associated mutant inhibits the UPR-associated activity of wt-VAPB. Cells
harboring the mutant thus become exposed to ER stress, making it vulnerable and thereby
resulting in motor neuron degeneration. Secondly, the ALS-associated mutant disrupts the
binding of wt-VAPB to FFAT-motif-containing proteins, leading to abnormal lipid
transport and biosynthesis and, eventually, to slow motor neuron degeneration. Lastly, the
ALS-associated mutant impaired the secretion or release of hVAP MSP domain or other
factors triggered by VAPB respectively, to illicit a yet undetermined non-cell-autonomous
defect which affects the viability of motor neurons due to decreases signaling by Eph
receptors and other receptors. The motor neurons are especially vulnerable to VAPB
mutations because wt-VAPB is highly expressed in the cell where it supports the high rate
of lipid metabolism and transport that upkeep its exceptionally large size and complex
morphology. Perhaps, all these proposed mechanisms and factors may also work in
tandem to produce the key features of ALS pathology resulting in specific death of motor
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neurons.
1.4.2 Structural consequences of mutations
The first examination of the effect of the P56S mutation on the structure of VAPB
was done by Nishimura et al., (2004) using a 3D model of VAPB based on the nematode
MSP dimer structure (PDB: 1MSP). As shown in figure 2, the Proline residue at position
56 of VAPB creates an S-shaped loop between two short stretches of β-strand and splits
half of the β strands in VAPB into the top part of the β-sandwich and the other half of the
β-strand into the bottom part. The P56S mutation is then proposed to disrupt the S-shaped
loop to favor a new hydrogen-bond pattern that moves the short stretch of B stand that
lies in the bottom half of the β sandwich to the opposite side. This misfolding of VAPB is
thus proposed to cause the pathogenic effects observed.
Furuita et al., (2010) had also inferred the effects of the P56S mutation on the MSP
domain of VAPB from VAPA (P56S). As judged by the 1H, 15N HSQC spectra of P56S
and wt-VAPA MSP domain, the structure of P56S VAPA was not observed to differ
greatly from that of wt-VAPA. The author then suggested that since the MSP domain of
VAPA and VAPB share 82% amino acid sequence identity, their structures are probably
similar and hence the effects of the P56S mutation on the MSP domain of VAPA should
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be similar on VAPB. Their work further supports the proposal by Nishimura et al., (2004)
that the P56S mutation induces conformational changes within the MSP domain.
In a more direct examination, Kim et al., (2010) had utilized Far-UV CD
spectroscopy and the fluorophore 1-anilinonaphthalene-8-sulfonic acid (1, 8-ANS) to
probe for the effects of P56S on the MSP domain on VAPB. Their results indicated that
the P56S mutation induces conformational changes within the MSP domain causing an
exposure of hydrophobic patches that enhances the propensity of the mutated domain to
oligomerize.
1.5 A challenge to study misfolded proteins
Possible treatment of misfolding diseases such as ALS could exploit detailed
knowledge of protein folding and the prevention of abnormal folding. But it is
particularly challenging to study these misfolded proteins experimentally due to their
tendency to aggregate into amyloids. This is especially true for VAPB (P56S) which
formed large membranous aggregate when are over expressed in cultured cells.
Furthermore, these aggregates cannot be characterized in detail at the molecular level
because they are not crystalline and are too large to be studied by solution NMR
spectroscopy. The situation has improved dramatically as a result of recent progress in the
application of solid-state NMR spectroscopy and of successes in growing nano- or
microcrystals of small peptide fragments that have characteristics of amyloid fibrils yet is
amenable to single crystal X-ray diffraction analysis. Also, with our recent discovery that
“insoluble proteins” can be solubilized in salt-free water (Song, 2009) we have
successfully for the first time, characterized the residue-specific conformation of




To fully understand the molecular mechanism underlying the VAPB mutation-
causing ALS, one essential step is to structurally characterize the wild-type VAPB MSP
domain, followed by the assessment of the consequence of the Pro56Ser and Thr46Ile
mutation. Here I investigated the structure, thermodynamic stability, activity and has also
used heteronuclear NMR spectroscopy to gain residue-specific conformational properties
of wt-VAPB and its related T46I and P56S mutant. It is hoped that the results gathered in
this study will provide a structural rationale on how the P56S mutation may lead to
ALS8.
In this thesis, we also found a difference in the distribution of conserved prolines
between VAPA and VAPB. Other than Pro-63 in the VCS of VAPA MSP domain which
has been studied by Nakamichi et al., (2011), two other prolines at position 13 and 97
were also substituted in wt-VAPB. Here, I investigated whether the substitutions of Gln-
13, Ala-63 and Thr-97 to a Proline residue affected the structural characteristics of VAPB
(P56S). It is hoped that by having a deeper understanding of the effect of the different






2.1 Cloning of the MSP domain of hVAPs
To obtain the gene which encodes for the MSP domain (residues 1−125) of
hVAPs (VAPB and VAPA), 2 sets of primers (referring to table S1, VAPA and VAPA
_ANTI; VAPB and VAPB _ANTI) were designed based on the sequence of the VAPA
(GenBank: NM_003574.5) and VAPB gene (GenBank: NM_004738.4) The DNA
fragment was then amplified from a HeLa cell cDNA library by performing a PCR
reaction [ 95°C for 5 min, 30x (95°C for 30 sec, 55°C for 30sec, 72°C for 40sec) 72°C
10min, 4°C ∞].
The PCR product and a pET-32a vector (Novagen) were then double digested
with the restriction enzymes, BamHI and Xho1 (New England Biolab ) for 6hrs at 37°C
and then gel purified using QIAquick gel extraction kit (QIAGEN), following the
manufacturer’s protocol. The digested PCR product containing the coding sequence of
the MSP domain of hVAP was then ligated into the digested vector in an overnight
reaction at 4°C using T4 DNA ligase (New England Biolab). By performing this cloning
strategy, the MSP domain of hVAPwas fused to an N-terminal 6x histidyl tag linked with
a thrombin cleavage site (LVPRGS) both provided in frame by the pET-32a vector.
DH5-α E.coli (Novagen) competent cell was then transformed with the
recombinant plasmids and plated onto LB plates with Ampicillin (Sigma). Single colonies
were picked and grown overnight at 37°C in 3 ml of LB media with Ampicillin.
Overnight cultures were centrifuged to harvest the bacterial cells and plasmids were
subsequently isolated and purified with the GENEALL™ plasmid quick purification kit
(General Biosystem). Plasmids were screened by double digestion using BamH1 and
Xho1 and monitored in agarose electrophoresis gel. The entire nucleotide sequence of the
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recombinant VAPB MSP domain gene was verified by sequencing. Sequencing results
were analyzed with GeneRunner (Hastings Software, USA) and DNAMAN (Lynnon
Corporation, Canada). Correct clones were transformed into BL21 (DE3) E. coli
(Novagen) strain for expression.
2.2 Site directed mutagenesis
The point mutations: P12S, P56S, T46I, Q13P, A63P and T97P on MSP domain of
VAPB and P56S on VAPA were synthesized according to the QuikChange site-directed
mutagenesis kit (Stratagene). Briefly, two synthetic oligonucleotide primers (table S2)
containing the desired mutation were designed using the QuikChange® Primer Design
Program. A mutated plasmid containing the desired mutation is generated by performing
a PCR reaction [95°C for 5 min, 12x (95°C for 30 sec, 55°C for 60sec, 68°C for 13min)
4°C ∞] using a high fidelity DNA polymerase. Following temperature cycling, the 50ul
reaction product is treated with 2 units of DpnI (New England Biolabs). The DpnI
endonuclease (target sequence: 5´-Gm6 ATC-3´) is specific for methylated and
hemimethylated DNA and is used to digest the parental DNA template and to select for
the mutant plasmid. Following digestion, the mutant plasmid containing the desired
mutation is then transformed into DH5-α competent cell and plated onto LB plates with
Ampicillin. Single colonies were picked and grown overnight at 37°C in 3 ml of LB
media with Ampicillin. Overnight cultures were centrifuged to harvest the bacterial cells
and plasmids were subsequently isolated and purified with the GENEALL™ plasmid
quick purification kit (General Biosystem). The entire nucleotide sequence of the mutated
VAPB MSP domain gene was verified by sequencing. Sequencing results were analyzed
with GeneRunner (Hastings Software, USA) and DNAMAN (Lynnon Corporation,
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Canada). Correct clones were transformed into BL21 (DE3) E. coli (Novagen) strain for
expression.
2.3 Expression of recombinant protein
A single colony of E.coli BL21 (DE3) cells harboring the expression plasmid was
grown overnight at 37oC with shaking in 5ml of LB medium containing Ampicillin (0.1
mg/ml). A 5ml aliquot of this culture was diluted into 1L of the same medium and grown
at 37oC with shaking. When cell growth reaches the mid-log phase (OD600 of 0.6-0.8),
expression from the T7promoter was induced by adding IPTG (Sigma) to a final
concentration of 0.3mM. After growth was continued for another 16hrs at 20oC, cells
were harvested by centrifugation at 6000 rpm for 30 min at 4oC. The cell pellet was
frozen and kept at -20oC.
2.4 Extraction
The cell pellet from each 1L culture (2-3g wet weight) was thawed and
resuspended in 30ml lysis buffer (150mM NaCl, 50mM NaH2PO4, pH 7.4) with one
cØmplete protease inhibitor cocktail tablet (Roche) and sonicated on ice (Sonics
VibraCell) at 30% amplitude for 10 min (pulse: 1” on and 1” off). The suspension was
centrifuged at 18,000 rpm at 4oC for 20min. The supernatant containing soluble proteins
and pellet representing the insoluble cell fraction was then appropriately used for
subsequent purification or are discarded.
2.5 Purification under the native condition
The MSP domain of VAPB, EphA4 and the respective mutants of the MSP
domains: VAPA (P56S), VAPB (T46I), VAPB (P56S, Q13P), VAPB (P56S, A63P),
VAPB (P56S, T97P) and VAPB (P56S, Q13P, A63P, T97P) were purified under the
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native condition. The supernatant representing the fraction of soluble recombinant
proteins was first purified with immobilized metal affinity chromatography (IMAC).
30ml of the supernatant were applied onto 0.8ml (0.5ml for VAPB (T46I) and VAPA
(P56S); and 0.2ml for VAPB (P56S, Q13P), VAPB (P56S, A63P), VAPB (P56S, T97P)
and VAPB (P56S, Q13P, A63P, T97P) Ni2+-NTA agarose (QIAGEN) equilibrated with
equilibration buffer (150mM NaCl, 50mM NaH2PO4, pH 7.4). After the protein-Ni2+-
NTA mix was incubated for at least 1 hour with shaking at 4oC, the slurry was poured
into an empty column and the flow through was discarded.
For the MSP domain of VAPB, EphA4, VAPA (P56S) and VAPB (T46I), the
column with the slurry was washed with 10 column volumes (CV) of wash buffer
(150mM NaCl, 50mM NaH2PO4, 20mM Imidazole, pH 8.0) and 40 units of thrombin
was subsequently added to achieve in-gel cleavage of the 6x Histidyl tag.
For VAPB (P56S, Q13P), VAPB (P56S, A63P), VAPB (P56S, T97P) and VAPB
(P56S, Q13P, A63P, T97P), the column with the slurry was washed with 10 column
volumes (CV) of wash buffer (150mM NaCl, 50mM NaH2PO4, 20mM Imidazole, pH 8.0)
and eluted with 5 CV of elution buffer (150mM NaCl, 50mM NaH2PO4, 250mM
Imidazole, pH 8.0).
Dithiothreitol (DTT) was subsequently added to the released recombinant protein
to make up a final concentration of 100mM. DTT was not added to the released
recombinant EphA4 protein.
Recombinant proteins were further purified by an AKTA fast protein liquid
chromatography (FPLC) machine on a HiLoad™ 16/60 Superdex™ 200 prep grade
Column. For purification of Recombinant EphA4, the gel filtration column was
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equilibrated with PBS (300mM NaCl, 50mM NaH2PO4, pH 7.4). For the purification of
all VAPB related recombinant protein, 20mM β-mercaptoethanol was additionally added
to the equilibration buffer. The length of each run was 1.5CV. Fractions of 1ml were
collected and each peak fraction was analyzed by SDS-PAGE. Recombinant proteins
were pooled and concentrated using an Amicon Ultra-15 centrifugal filter device
(Millipore) with a 5kDa cut off.
The samples at each purification step were collected and analyzed by SDS-PAGE
with 4% stacking gel and 12% separating gel. The identities of all recombinant proteins
were verified by MALDI-TOF mass spectrometry.
2.6 Purification under the denaturing condition
VAPB (P56S) and VAPB (P12S) were found in the inclusion body and hence
purified under the denaturing condition. The pellet representing the fraction of insoluble
recombinant proteins was first dissolved in the denaturing buffer (50mM NaH2PO4, 8M
urea, pH 8.0) and enriched using 1ml of Ni2+-NTA agarose equilibrated with denaturing
buffer. After the protein-Ni2+-NTA mix was incubated for at least 1 hour with shaking at
room temperature, the slurry was poured into an empty column and the flow through was
discarded. 10 column volumes (CV) of wash buffer (50mM NaH2PO4, 8M urea, 20mM
Imidazole, pH 8.0) and eluted with 5 CV of elution buffer (50mM NaH2PO4, 8M urea,
250mM Imidazole, pH 8.0). 100mM of DTT was subsequently added to the eluted
fraction before it was further purified by reverse-phase HPLC on a C4 column (Vydac).
Elution and separation was achieved using a gradient of 0.5% (v/v) /min of
acetonitrile, containing 0.1% Trifluoroacetic acid (TFA) at a flow rate of 6ml/min. The
chromatography was monitored at both 215nm and 280nm. All the peaks were collected
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and lyophilized. The identities of all recombinant proteins purified by HPLC were also
verified by MALDI-TOF mass spectrometry.
The Pro56Ser and Pro12Ser samples precipitated upon addition of thrombin, thus
the 6x Histidyl tag was not removed.
2.7 Isotope labeling
The generation of the isotope-labeled proteins for NMR studies, followed a
similar procedure except that the bacteria were grown in M9 medium (171.g/L Na2HPO4,
3g/L K2HPO4, 0.5g/L NaCl, 1g/L (NH4)2SO4, 4g/L glucose, 1mM MgSO4 2mg/L
Thiamine (VB1) and 75mg/L Amplicilin) with the addition of (15NH4)2SO4 for 15N
labeling and (15NH4)2SO4/[13C]glucose for 15N-/ 13C-double labeling.
2.8 Purification of Peptides used in binding assay
The Nir2 peptide (EEEFFDAHE) was purchased from Genesis Biotech Inc. and
further purified by HPLC on a reverse-phase C18 column (Vydac) before lyophilization.
The powder of the peptide following lyophilization were weighed and then dissolved in
10 mm phosphate buffer. The pH was adjusted to pH 6.5 before it was used for binding
studies.
2.9 Measurement of protein concentration
Protein concentrations were calculated with the extinction coefficient of the
Tryptophan and Tyrosine residues. All VAPB related recombinant proteins have an Ext.
coefficient of 8855cm -1 M -1(assuming ALL Cys residues appear as half cysteines).
EphA4 has an Ext. coefficient of 32930cm -1M -1 (assuming ALL Cys residues appear as
half cysteines). With the absorbance at 280nm in the presence of 6M guanidine
hydrochloride (Sigma) and the extinction coefficient, the protein concentration was
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calculated with the formula A=ε*c*l [A= absorbance, ε=extinction coefficient (M-1cm-1),
l =path length of cuvette (cm) and c= protein concentration (M)].
2.10 Circular Dichroism (CD) spectroscopy
The secondary structure of all the recombinant proteins were determined with a
Far UV (190-260 nm) circular Dichroism (CD) of a 20μM protein solution in 10mM
phosphate buffer, pH 6.5. Measurements were carried out in a Jasco J-810
spectropolarimeter (Jasco Corporation, Tokyo, Japan) at 25oC using 0.1 cm path length
stoppered cuvettes. The spectra correspond to the average of three scans. Each scan was
recorded using a scan speed of 50 nm /min, resolution 0.1nm, and band width 2nm. For
data processing, the baseline was subtracted.
To study the effects of pH on the secondary structure of the recombinant proteins,
far UV spectrums were collected in the pH range of 3.0 to 9.0. The pH was adjusted by
addition of microliter amounts of dilute Hydrochloric acid or sodium hydroxide. For data
processing, the spectrum was multiplied with a dilution factor that results from the
additional volume during pH adjustments.
2.11 Urea unfolding
To measure the thermodynamic stability of the VAPB MSP domain and of its
mutants, we varied the urea concentration from 0 to 8 M and monitored the change in the
ellipticity at 222 nm of a 50uM protein sample by collecting a series of far-UV CD. The
unfolding curve was constructed by plotting the ellipticity values at 222 nm versus the
molar concentration of urea. By assuming a two-state unfolding process, the stability free
energy (ΔG°N−U) was determined using the two equations (Gupta et al, 1996) below. The
values of the Gibbs energy change (kcal mol-1) determined from the measurements were
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plotted and analyzed using LEM, the linear free energy model.
Where: R = molar gas constant 1.9858775 cal K−1 mol−1
T = Temperature = 20°C + 273.15 = 293.15 K
y = measured optical property in a particular denaturing condition
yN = optical properties of the protein in the fully native states under the
same condition
yD = optical properties of the protein in the fully denatured states under the
same condition
Where: m = the slope of the ∆GN -U versus [denaturant] plot
∆G0N -U = value of ∆GN -U at [denaturant] = 0 M
2.12 ITC Characterization of Binding Activity
Isothermal titration calorimetry (ITC) experiments were performed using a
Microcal VP-ITC machine. All titrations were conducted in 10mm phosphate buffer, pH
6.5, at 25 °C. All samples were degassed for 15 min to remove bubbles before the
titrations to prevent the formation of bubbles. The Nir2 peptide was loaded into a 300ul
syringe, while all recombinant VAPB related MSP protein was placed in a 1.8ml sample
cell. The concentration of sample in the syringe is typically 20-fold that of the sample in
the cell. To subtract the effects due to sample dilution, control experiments with the same
parameter settings were also performed for the peptide and buffer. To obtain
thermodynamic binding parameters, the titration data after subtraction of the blank values




All NMR data were collected at 25 °C on an 800 MHz Bruker Avance
spectrometer equipped with a shielded cryoprobe. For 1H, 15N HSQC characterization,
the wild-type VAPB MSP sample and all related MSP mutants except P56S and P12S
were prepared in 10 mM phosphate buffer (pH 6.5) with an addition of 10% D2O for the
deuterium lock for the NMR spectrometers. In contrast, the Pro56Ser and Pro12Ser
mutants were dissolved in salt-free water and 10% D20.
For achieving sequential assignments, triple-resonance experiments, including
HNCACB, CBCA(CO)NH, and HNCO, were conducted for both wild-type, Pro56Ser
and T46I MSP domains on doubly labeled samples at a protein concentration of 800μM
(for wt-VAPB and P56S) and 300μM for T46I.
For NOE analysis, 15N-edited HSQC-TOCSY and HSQC-NOESY spectra were
recorded for the 15N-labeled Pro56Ser mutant.
The 1H chemical shift was referenced directly to 2,2-dimethyl-2-
silapentanesulfonic acid (DSS), whereas the 15N and 13C chemical shifts were indirectly
referenced to DSS (Wishart et al., 1995). The secondary structure mapping based on N,
HN, CA, CB, CO, and HA chemical shifts were performed using DANGLE in CCPNMR
(Vranken et al., 2005 and Cheung et al., 2010).
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Chapter 3
Studies on the MSP domain of VAPB, VAPB (P56S) and VAPB (T46I)
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3 Results
3.1 Studies on the wt-VAPB MSP domain
The wt-VAPB MSP domain (1-125) has been successfully cloned, expressed and
purified the recombinant the using a prokaryotic system under the native condition. The
purified wt-VAPB MSP domain is highly soluble in the buffer systems used. CD and
NMR spectroscopy was utilized to study its structural properties.
3.1.1 Structural properties of the wt-VAPB MSP Domain
As shown in Figure 3a, at pH 6.5, the wt-VAPB MSP domain has a far-UV CD
spectrum typical of a β-dominant secondary structure, with the maximal negative signal
at ~218 nm and positive signal at ~199 nm. Upon lowering the pH value, the intensity of
the positive signal at ~199 nm reduces gradually and eventually disappeared at pH 3.5.
In addition, at pH 3.5, the maximal negative signal shifted from ~218 nm to ~212 nm,
implying that the wt-VAPB MSP domain may be unfolded to some degree.
To gain detailed knowledge about the acid-induced unfolding, a series of two-
dimensional 1H-15N HSQC spectra on the 15N-labeled wt-VAPB MSP domain was
collected with pH values varying from 6.5 to 2.5. Consistent with the CD results, at
neutral pH the wild-type MSP domain has a HSQC spectrum typical of a well-folded
protein (Figure 3b). When the pH was lowered down to 5.5 and 4.5, slight shifts of the
HSQC peaks was observed (Figure 3c). This indicates that no large conformational
change occurs which is also consistent with the CD results. However, upon lowering the
pH value to 3.5, two sets of peaks can be observed in the HSQC spectrum (Figure 3d).
One set of the HSQC peaks is very similar to those at pH 6.5 with very large spectral
dispersions while another newly appeared set of peaks have a dramatically-reduced
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dispersion which resembles that of an unfolded species. When the sample was further
acidified, the intensity of the peaks from the unfolded population increased, and at pH 2.5
only the peaks set from the unfolded species could be observed. When the sample pH
value was adjusted back to 6.5, the unfolded state could fold back to the well-folded state,
indicating that the acid-induced unfolding is reversible for the wt-VAPB MSP domain.
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3.1.2 Stability of the wt-VAPB MSP Domain
Next, Dr Shi Jiahai had measured the thermodynamic stability energy by
monitoring the ellipticity change at 222nm during urea-unfolding. As seen in Figure 4,
the unfolding process appears highly cooperative, starting at the urea concentration of
~3.5 M and ending at ~5.1 M. Fitting of the unfolding data yields the free energy of the
conformational stability (ΔG0N-U) to be 7.40 ± 0.41 kcal/mol. In general, thermodynamic
stability energy for most proteins ranges from 5 to 20 kcal/mol under physiological
conditions. This implies that the thermodynamic stability of the wild-type MSP domain is
not very high.
3.1.3 Binding Activity of the wt-VAPB MSP Domain
The thermodynamic parameters for the binding between the wt-VAPB MSP domain
and the FFAT-containing motif of the Nir2 protein were also measured by ITC (Figure 5).
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The wt-VAPB MSP domain is able to bind tightly to the FFAT-motif containing peptide
EEEFFDAHE derived from the human Nir2 protein, with a dissociation constant (KD) of
0.65 µM. As such, the CD and ITC results together clearly demonstrate that at neutral pH,
the wild-type MSP domain is both structurally well-folded and functionally active.
3.1.4 Crystal Structure of the wt-VAPB MSP Domain
I have also succeeded in optimizing the conditions required to obtain crystals of wt-
VAPB MSP domain with good diffraction qualities. The crystal structure at 2.5 Å
resolution with a final R-factor of 0.2068 (Rfree=0.2655) was solved by Dr Shi jiahai. The
wt-VAPB MSP domain adopts a seven-stranded immunoglobulin-like β sandwiches with
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s-type topology. In the final model, one asymmetric unit contains two MSP molecules
which form a dimer linked through an intermolecular disulfide bridge between two Cys53
residues (Figure 6a). On the other hand, based on the FPLC and DLS characterization,
the wt-VAPB MSP domain was shown to be a monomer in solution. Henceforth, the
dimer observed here in the wt-VAPB MSP domain structure is probably an artifact arising
due to crystallization at a very high protein concentration (10 mg/ml). The two individual
molecules in the dimeric wt-VAPB MSP structure are very similar, with a RMS deviation
of only 0.41 Å for the backbone atoms.
The wt-VAPB MSP domain also possess two unique S-shape loops over residues
Gln11-Pro12-Gln13-His14 and Arg55-Pro56-Asn57-Ser58, which appear to be stabilized
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by the cis-peptide bond conformation constrained by Pro12 and Pro56 respectively
(Figure 6c). The first S-shape loop connects the β-strands Ser9-Leu10 and Glu15-Arg19
whereas the second S-shape loop connects the β-strands Cys53-Val54 and Gly59-Ile61
(Figure 6d). In particular, it has been speculated that because of being critically located in
the S-shape loop, Pro56 might play a key role in stabilizing the MSP domain and
consequently its mutation would result in insolubility.
3.2 Studies on the Pro56Ser Mutation
To address the consequence of the ALS8-causing P56S mutation, the P56S mutant
of the wt-VAPB MSP domain was generated by using site-directed mutagenesis. The
recombinant VAPB (P56S) protein was found in the inclusion body when expressed using
a prokaryotic system. All attempts to refold it had failed due to severe precipitation.
However, we recently discovered these “insoluble proteins” could be in fact solubilized
in salt-free water and now this approach has also been used by other groups to
characterize insoluble proteins (Amos et al., 2009 and Delak et al., 2009).  Therefore,
P56S-VAPB was purified under the denaturing conditions in the presence of 8M urea
using affinity chromatography followed by RP-HPLC on a C4 column. The lyophilized
VAPB (P56S) protein is then dissolved in salt free water.
The purified VAPB (P56S) protein is highly soluble in salt free water and has an
acidic pH due to the remaining TFA from the HPLC solvent. Far-UV CD and NMR
spectroscopy was then utilized to study its structural properties.
3.2.1 Structural Consequences of the Pro56Ser Mutation
As shown in Figure 7a, at pH 3.5 the VAPB (P56S) MSP domain has a far-UV CD
spectrum characteristic of a predominantly-unstructured protein, with its maximal
45
negative signal at ~199 nm and without any positive signal. The mutant remains highly
unstructured up to a pH of 5.5 and further attempts to neutralize the pH causes it to
precipitate.
Next, the effect of salt on the conformational properties of VAPB (P56S) was
explored by far-UV CD. As shown in Figure 7b, the overall shapes of the CD spectra are
still similar at various pH and salt concentrations up to 10mM, indicating that the mutant
remains similarly disordered under these conditions. However, when the pH value
reached 6.5 for the sample containing 10mM salt, the protein precipitated immediately
and consequently the CD signal disappeared.
NMR spectroscopy was also utilized to study the effect of pH and salt on the VAPB
(P56S) MSP domain. As seen in figure 7c, and also consistent with the above CD results,
at pH 3.5, the mutant has a HSQC spectrum characteristic of an unfolded protein without
any tight tertiary packing, with only 0.8 and 11 ppm dispersions over 1H and 15N
dimensions respectively. Interestingly, at pH 3.5 many HSQC peaks of the mutant are
superimposable to those from the unfolded population of the wild-type at pH 3.5 (Figure
7c), implying that the mutant might have a conformational ensemble similar to that of the
unfolded population of the wild-type at pH 3.5. However, unlike the wt-VAPB MSP
domain which could reversibly fold back at pH above 4.5, VAPB (P56S) at pH 4.5 and
5.5 still remains highly unstructured as no significant dispersion change is observed for
their HSQC spectra (Figures 7d and 7e). At pH 6.5, the protein completely aggregated
and consequently no HSQC peaks could be detected. Also consistent with the CD results,
at pH 3.5, upon adding varying amount of salt, no significant change of spectral
dispersions occurs and only some peaks undergo slight shifts probably due to the non-
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specific interactions with the salt ions. This thus suggests that the salt has no considerable
effect on the conformation of VAPB (P56S).
3.2.2 Residue specific Conformational Properties of VAPB (P56S)
In order to gain knowledge about the residue-specific conformational properties of
VAPB MSP domain, both wild-type and VAPB (P56S) MSP domains were isotope-
labeled and a series of three-dimensional heteronuclear NMR experiments were
collected. For the wild-type MSP domain, NMR HSQC resonance peaks were detected
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and assigned for almost all residues except for several short stretches over Gln11-His14,
Ser84-Lys87 and Lys110-Glu112. For the Pro56Ser mutant, probably due to more severe
conformational exchanges on the µs-ms time scale or/and dynamic aggregation in the
unfolded state, more NMR HSQC resonance peaks were invisible, including fragments
Ala48-Arg51, Met72-Gln74, Pro80-Phe94, Pro111-Ser117 and Val122-Leu125.
With the CA, CO and HA chemical shift of each resonance peak, the chemical shift
deviations from their random coil values was calculated for both native and P56S MSP
domains. As seen in Figure 8, the wild-type MSP domain has very large CA and CO
deviations typical of a fully-folded protein, while the P56S mutant has dramatically
reduced deviations characteristic of an unfolded protein. It also appears that in the P56S
mutant, the native β-sheet secondary structure is totally eliminated. Instead, based on the
negative HA chemical shift deviations (Figure 8c), it appears that non-native helical
conformation is weakly populated over the sequence. In addition, the software DANGLE
in CCPNMR was used to map the secondary structures based on chemical shift
deviations. The results indicate that in solution the wild-type wt-VAPB MSP domain has
secondary structure patterns completely consistent with those in the crystal structure. By
contrast, the VAPB (P56S) mutant has random coil conformation almost over the whole
sequence except for the presence of a weakly-populated helix over residues Thr97 to
Glu108 (Figure 8c). Interestingly, in the wild-type MSP structure, a helix is also found
but much shorter, only spanning over residues Ala104 to Glu108.
The 15N-edited HSQC-NOESY spectrum was also analyzed, but no long-range
NOEs could be identified, strongly suggesting the absence of any stable tertiary packing
in the VAPB (P56S) mutant. As shown in Figure 9, except for the missing residues,
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sequential dNN(i, i + 1) and medium-range dαN(i, i + 2) NOEs could be observed over the
majority of the sequence, suggesting that the non-helical conformation is indeed
populated to some degree. However, dNN(i, i + 2) NOEs could be found only over two
segments (Gly33−Thr46 and Thr97−Glu108), while only two dαN(i, i + 3) NOEs could be
identified between Ala104 and Lys107 and between Val105 and Glu108. These results,
together with a complete lack of any dαN(i, i + 4) NOE, imply that the non-native helical
conformation is very dynamic and only weakly populated in the P56S-VAPB (Delak et
al., 2009).
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3.2.3. Binding activity VAPB (P56S)
NMR HSQC titrations were also utilized to examine whether the P56S-VAPB
mutant is still able to bind to the Nir2 peptide in solution. However, the obtained result
demonstrates that there is no detectable binding at pH 3.5 even in the presence of 10mM
salt, at a molar ratio even up to 1:50 (data not shown). Unfortunately, further attempts to
detect the binding interaction at a physiologically relevant pH failed because of severe
aggregation of the protein upon neutralizing the pH.
3.2.4. Structural Consequences of the Pro12Ser Mutation
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As mentioned above, there are two characteristic S-shape loops present in the wt-
VAPB MSP domain. To investigate if Proline 12 also plays a similar role as Proline 56,
Proline 12 was mutated to Serine by using site-directed mutagenesis. Interestingly, the
P12S mutant indeed became insoluble and was only found in the inclusion body. As such,
we purified the recombinant VAPB (P12S) protein as described above and dissolve it in
salt free water. As judged by the CD results, in salt-free water (Figure 10a), VAPB (P12S)
is highly unstructured at pH values below 5.5 but becomes severely aggregated at pH 6.5.
This is further supported by the HSQC spectra at different pH values. At pH 6.5, no
HSQC peaks could be detected even with the spectral contour down to the noise level
(Figure 10e), suggesting a drastic aggregation at this pH. In addition, many HSQC peaks
of the Pro12Ser mutant are also superimposable to those of the Pro56Ser mutant (Figure
10b). This implies that the VAPB (P12S) and VAPB (P56S) mutants might have similar
conformational properties over a large portion of the molecules.
3.3. Studies on the Thr46Ile Mutation
In addition to the P56S mutation, T46I was also recently identified to cause ALS8
(Chen et al., 2010). To address the consequence of the ALS8-causing T46I mutation, the
T46I mutant of wt-VAPB MSP domain was generated by using site-directed mutagenesis.
Although like VAPB (P56S), when expressed in a prokaryotic system, a large portion of
the recombinant protein still existed in inclusion bodies, there was also a significant
portion of soluble VAPB (T46I). Subsequently, VAPB (T46I) was purified under the
native condition similar to wt-VAPB. The purified VAPB (T46I) mutant was soluble in
the buffer systems used but tends to aggregate at high concentration (~10mg/ml) and high
temperature. CD and NMR spectroscopy was utilized to study its structural properties.
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3.3.1. Structural Consequences of the Thr46Ile Mutation
As shown in Figure 11a, at pH 6.5, the VAPB (T46I) MSP domain has a far-UV CD
spectrum typical of a β-dominant secondary structure, with the maximal negative signal
at ~218 nm and positive signal at ~199 nm. The overall shape of the CD spectra is also
highly similar to that of the structured wt-VAPB but completely different from the
unstructured VAPB (P56S). This implies that VAPB (T46I) has a native-like secondary
structure and that this mutation, unlike P56S did not result in the elimination of the native
structure of wt-VAPB nor cause aggregation at neutral pH.
Next, a two-dimensional 1H-15N HSQC spectra of the 15N-labeled VAPB (T46I)
MSP domain was collected at pH 6.5. As seen in figure 11b, and also consistent with the
above CD results, at pH 6.5, the mutant has a HSQC spectrum characteristic of a well-
folded protein, with very large spectral dispersions that extends 3.5 ppm and 25 ppm over
the 1H and 15N dimensions respectively. Many HSQC peaks of the VAPB (T46I) mutant
are also superimposable to the wt-VAPB at pH 6.5, implying similar conformational
properties over a large portion of the molecules.
3.3.2. Residue-Specific Conformational Properties of VAPB (T46I)
In order to gain knowledge about its residue-specific conformational properties, the
MSP domain of VAPB (T46I) was double isotope-labeled (15N and 13C) and a pair of
triple-resonance NMR spectra, namely HNCACB and CBCA(CO)NH was acquired. For
the VAPB (T46I) MSP domain, NMR HSQC resonance peaks were detected and assigned
for almost all residues except for several short stretches over Glu11-His14, Ile46-Tyr52,
Glu82-Ser84 and C-terminal Phe123- Leu125. Probably due to more severe
conformational exchanges, more NMR HSQC resonance peaks were invisible over the
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stretch of Ile46-Ala50 as compared to wt-VAPB. As compared to wt-VAPB, several
HSQC peaks have also shifted dramatically. Together these data suggests that the T46I
mutations causes part of the MSP domain to become more flexible or are more exposed
as compared to wt-VAPB.
Next, the Cα and Cβ chemical shift of each resonance peak for VAPB (T46I) was
compared with wt-VAPB MSP domain. As seen in figure 11c, d, e the VAPB (T46I) has
very large and similar Cα, and Cβ deviations typical of a fully-folded protein and are
almost identical to those of wt-VAPB. To sum up, these results provides the strongest
evidence that the T46I mutant assumes a three-dimensional structure highly similar to
that of wt-VAPB, and intriguingly, the short regions which harbors the Thr46 seems to
become more flexible as well.
3.3.3. Stability of the VAPB(T46I) MSP Domain
The thermodynamic stability energy of VAPB (T46I) was also measured by
monitoring the ellipticity change at 222nm during urea-unfolding. As seen in Figure 12a,
unlike wt-VAPB with a cooperative unfolding transition, VAPB (T46I) shows a non-
cooperative transition as well as reduced stability. VAPB (T46I) starts unfolding at a urea
concentration of ~1.6 M and shows no ending even at 8 M, while WT starts at ~3.5 M
and ends at ~5.1 M. As a result of losing the cooperative unfolding transition, the precise
energy of thermodynamic stability could not be fitted out from the VAPB (T46I)
unfolding curve.
The loss of a cooperative unfolding transition of VAPB (T46I) implies that its
tight tertiary packing is disrupted to some degree (Song et al., 1999 and Wei et al., 2005)
and consequently the T46I molecule may be more accessible to partially- or highly
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unfolded states prone to aggregation. Indeed, we have observed that VAPB (T46I) is
prone to aggregation at high protein concentrations and temperatures. For example, while
at 45°C the et-VAPB MSP domain showed no precipitation and has almost no change of
the upfield peaks in the one-dimensional NMR proton spectra (Figure 12b), a large
portion of the VAPB (T46I) mutant precipitated at ~42°C and the remaining protein has a
dramatic structural alteration as evidenced from the changes of the upfield peaks (Figure
12c).
3.3.4. Binding Activity of VAPB (T46I) MSP Domain
The thermodynamic parameters for the binding between the VAPB (T46I) MSP
domain and the FFAT-containing motif of the Nir2 protein were also measured by ITC
(Figure 13a). The VAPB (T46I) MSP domain is still able to bind to the FFAT-motif
containing Nir2 peptide EEEFFDAHE with a dissociation constant (KD) of 2.20 µM.
Thus, unlike P56S which abolishes the ability of VAPB to interact with FFAT-motif
containing proteins, the T46I mutation merely causes a reduction in affinity by ~3 times
as compared to wt-VAPB.
HSQC titrations were also utilized to visualize the binding of the wt-VAPB and
VAPB (T46I) MSP domain to the Nir2 peptide. As shown in Figures 13b and 13d, in wt-
VAPB, for the residues directly contacting the peptide (Kaiser et al., 2005 and Shi et al.,
2010), their HSQC peaks mostly disappeared at a molar ratio of 1:2 (wt-VAPB/Nir2),
while for the residues not directly contacting but close to the binding interface, their
HSQC peaks shifted. Intriguingly, due to the reduced affinity, the addition of the Nir2




3.3.1. Interactions of VAPB MSP domain with the EphA4 receptor
As mentioned in section 1.3.3.3, the MSP domain was identified by Tsuda et al.,
(2008) to be a novel ligand for the EphA4 ligand binding domain. To gain insights into
the underlying structural basis, I attempted to gain thermodynamic parameters for the
EphA4-wt-VAPB-MSP binding by ITC but unfortunately a complex ITC profile was
obtained. This implied that the binding may be involved in muti-sites or/and multi-steps.
The EphA4-wt-VAPB-MSP complex also failed to crystallize after extensively screened
a variety of buffer conditions. As such, NMR HSQC titrations were utilized to further
gain molecular details for the binding interaction between EphA4 and the MSP domain.
First we monitored the change of the HSQC spectra of 15N labeled wt-VAPB - and
VAPB (T46I) - MSP domain upon the gradual addition of the unlabeled EphA4 ligand
binding domain. Because the EphA4 ligand binding domain was intolerable to reducing
agents, DTT which was used in the buffer solubilizing wt-VAPB and VAPB (T46I) has to
be removed. In addition, the titration was done at pH 8.0 to match the pH used in the in
vitro study by Tsuda et al., (2008). The removal of the reducing agent produced striking
differences in the HSQC spectra of 15N labeled wt-VAPB but not 15N labeled VAPB
(T46I). As seen in figure 14a, many of the HSQC resonance peaks of wt-VAPB showed
line broadening. This implies that in an oxidizing environment, the wt-VAPB MSP
domain may undergo conformational exchanges in the μs-ms time scale possibly due to
aggregation. It is unlikely that wt-VAPB formed a tight oligomer as it was purified as a
monomer even in the oxiding environment. In addition, as mentioned, Kim et al., (2010)
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has already provided clear evidences that the MSP domain of VAPB does not contribute
to VAPB oligomerisation.
As shown in Figure 14a, introduction of unlabeled EphA4 ligand binding domain
to 15N labeled wt-VAPB MSP domain induced shifts of few HSQC resonance peaks and
more significantly disappearance of several peaks. If the residues with significantly
perturbed HSQC resonance peaks were mapped back to the MSP structure (PDB: 3IKK),
it appears to be located on the E-F loop and several β-strands: C-strand carrying Thr46,
F- and G-strands (Figure 15a). By contrast, addition of EphA4 to 15N labeled VAPB
(T46I) resulted in almost no disappearance of HSQC peaks with only peak shifts for
some residues (Figures 14b and 15b). These results indicate that the T46I mutation
dramatically disrupts the binding ability of the MSP domain to EphA4.
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We further study the interaction by monitoring the HSQC spectra of 15N labeled
EphA4 ligand binding domain upon the gradual addition of unlabeled wt-VAPB or
VAPB (T46I) MSP domain. As shown in Figure 16a, addition of the wt-VAPB MSP
domain protein even at a ratio of 1:2 (EphA4/wt-VAPB) induced disappearance or
intensity-reduction of several EphA4 HSQC resonance peaks, together with shifts of
some peaks. If more wt-VAPB MSP domain protein was added, almost all EphA4 peaks
disappeared at a ratio of 1:8. Again, when the residues with perturbed peaks were mapped
back to the EphA4 structure, the D-E, G-H and J-K loops were observed to be involved in
binding to the MSP domain (Figure 17a). These loops were also previously established
by Qin et al., (2010) to directly contact its ephrins ligands. By a sharp contrast, addition
of the VAPB (T46I) MSP domain caused almost no peak disappearance, but only shifts
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of few peaks (Figures 16b and 17b). Together, these results indicated that the T46I
mutation dramatically eliminates the binding capability of the MSP domain to EphA4.
To understand the underlying mechanism for the significant disappearance of both
MSP and EphA4 HSQC resonance peaks, we measured the radius of the EphA4 ligand
binding domain by dynamic light scattering (DLS) in the presence of both wt-VAPB -
and VAPB (T46I) - MSP domains at different molar ratios but no significant changes
were observed. In addition, size exclusion chromatography of EphA4 and wt-VAPB
mixed in a 1:1 ratio at high concentrations yielded only free proteins in their monomeric
state. This implies that the binding triggers no formation of the tight EphA4-MSP
complex and no significant oligomerization. As such, the disappearance of the MSP and
EphA4 HSQC peaks is most likely to arise from the increase of conformational
exchanges on the µs-ms time scale upon binding.
Next the binding of wt-VAPB MSP domain and EphA4 was tested to see if it can
be interrupted by the presence of the FFAT motif containing Nir2 peptide. Intriguing as
seen in figure 18b, unlike before where the addition of wt-VAPB could induce significant
shift/disappearance of several EphA4 HSQC resonance peaks, only a small portion of
EphA4 residues were perturbed in the presence of the Nir2 peptide. Also as seen in figure
18a, the addition of Nir2 peptide did not cause significant changes in the HSQC of
EphA4. These observations strongly implied that the binding of the Nir2 peptide to the
MSP domain would inhibit its binding to EphA4. This inhibition is most likely due to the
fact that EphA4 and the Nir2 peptide may have overlapped binding interfaces on the MSP
domain.  It is unlikely that a structural change in the MSP domain could interrupt this
binding because it had been demonstrated by Kaiser et al., (2005) that the MSP domain
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showed no significant change upon binding to ORP1, a FFAT-containing peptide.
3.4. Discussion and conclusion
Two mis-sense point mutations in the human VAPB gene are associated with a
familial form of motor neuron disease that has been classified as Amyotrophic Lateral
Sclerosis type 8 (ALS8). The pathogenic mutations have been exhaustively studied by
several groups and we now have a plethora of knowledge on the possible mechanisms
responsible for the specific death of motor neurons in ALS8. However, so far, no study
on the structure and stability of the wild-type MSP domain has been reported, and in
particular, the structural consequences of this mutation remain completely unknown.
The wild-type hVAPB MSP domain is shown to be well-folded at neutral pH, with
a three-dimensional structure highly similar to that of the rVAPA MSP domain. The wild-
type MSP domain can undergo a reversible acid-induced unfolding, is fully functional in
tightly binding to the FFAT-motif containing peptide derived from the Nir2 protein, with
a Kd of 0.65 uM and has a moderately low stability free energy of 7.40 kcal/mol.
Our results also clearly demonstrate that the Pro56Ser mutant remains lacking of
native structure under a variety of pH values and salt concentrations. This implies that the
P56S mutation is able to eliminate the ability of the mutated sequence to fold into the
native structure adopted by the wild-type MSP sequence. This is surprising as it is
previously thought that the P56S mutation would only remove a kink between the
stretches of ß-strand, changing the hydrogen bond pattern but not completely eliminate its
structure. As seen in Figure 6c, Proline 56 is not only located at the central position of the
hydrophobic core formed by the side chains of the hydrophobic residues but also in the
characteristic S-shape loop, adopting the unusual cis-peptide bond conformation. As
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such, the replacement of the hydrophobic Proline 56 by the polar Serine is anticipated to
impose two effects. The first is to abolish the S-shape loop and significantly increase the
backbone flexibility around Proline 56; and secondly is to destabilize the hydrophobic
core upon introducing polar side chain of Serine. The importance of the two S-shape
loops in maintaining the structural integrity of the MSP domain is further supported by
our experimental results about the abolishment of its structure and solubility as triggered
by the Pro12Ser mutation. Because the thermodynamic stability of the hVAPB MSP
domain is also not very large, the two destabilizing effects appear sufficient to abolish the
ability of the mutant sequence to form the native structure of the wild-type MSP domain.
The elimination of the tight tertiary structure in P12S and P56S results in the
exposure of hydrophobic side chains. The exposed hydrophobic side chains have a large
tendency to be clustered together to form aggregates, unless the attractive hydrophobic
interaction can be suppressed by the intrinsic repulsive electrostatic interactions in salt-
free water, with the solution pH several units away from the protein isoelectric point (pI).
Indeed, the pI values of the P56S and P12S mutants were estimated to be ~7.5, thus
explaining the observation that the Pro56Ser and Pro12Ser proteins would precipitate
immediately after the solution pH was adjusted to neutral. Unsurprisingly, under the
physiological condition, the pH is ~7.0 and the concentration of the salt ions is ~150 mM.
As a result, under the physiological-relevant pH values, the repulsive electrostatic
interactions are relatively small and also will be further screened out by the presence of
~150 mM salt. Consequently, in vivo the hydrophobic interaction will become dominant
in the Pro56Ser mutant because of both neutral pH and high salt concentration, thus
resulting in severe aggregation.
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Unlike the Pro56Ser mutation, the Thr46Ile do not result in the elimination of the
native structure of the MSP domain. This came as a surprise as it has been suggested by
Chen et al., 2010 that the theoretical pathogenicity of this mutation as calculated by the
program PMut is greater than that of the VAPB (P56S). Despite this, the Thr46Ile
mutation does abolish the cooperative urea-unfolding transition and reduce the
thermodynamic stability of the MSP domain. The Thr46 residue lies in a loop that
connects the D and E β-stand. The D β-stand harbors the Cys53 residues that formed an
intermolecular disulphide bond with another MSP domain as shown in the structure
(figure 6a). Pro56 lies immediately after this D β-stand and as discussed above is critical
in maintaining a compact hydrophobic core. As such, replacement of the Threonine
residue with a polar uncharged side chain to a hydrophobic side in isoleucine might have
two effects.  First, the long side chain of Isoleucine may disrupt the hydrophobic
interaction network of the domain and consequently destabilize or decrease the overall
compactness of the hydrophobic core resulting in the observed reduced thermodynamic
stability. Secondly, the T46I mutation might also affect the ability of the S-shape loop
created by Pro56 in maintaining structural integrity. The reduced stability of VAPB
(T46I) allows the MSP domain to more easily access the partially- or/and highly-
unfolded intermediates which are prone to aggregation (Li et al., 2006 and Song et al.,
2009). Indeed, if compared to the wt-VAPB MSP domain, the VAPB (T46I) domain is
much more prone to aggregation at high protein concentration and temperature.
We have also suggested that the segment of the MSP domain bearing the mutation
could be more dynamic. The T46I mutation could also change the global dynamics of the
MSP domain, inducing conformational changes that eventually lead to as exposure of
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hydrophobic patches which becomes accessible to solvents. The exposed hydrophobic
patches in turn, cause the mutated protein to be prone to aggregation at high
concentration.
We have also demonstrated that the Thr46Ile mutation does not abolish the ability
of VAPB (T46I) to interact with FFAT containing Nir2 peptide. Indeed, the T46I mutation
merely causes a reduction in affinity by ~3 times as compared to wt-VAPB. Intriguingly,
in other studies a VAPB mutant with Thr46Ala and Thr47Ala mutation was found to not
to interact with FFAT containing proteins ORP2, ORP3, or ORP7 as demonstrated by
Kaiser et al., (2005) and Loewen et al., (2005) using yeast cells and also by Suzuki et al.,
(2009) using pull-down analysis. In addition, Suzuki et al., (2009) has demonstrated that
the VAPB (T46A, T47A) mutant showed proper ER localization and that their Triton X-
100-soluble amounts were comparable to that of wt-VAPB. In contrast the T46I mutation
in VAPB as shown by Chen et al., (2010) aggregates in cells and have increased
insolubility in Triton X-100 buffers. Together the data presented here might have
suggested that the mutation of Thr46 to Isoleucine or Alanine in the VCS of the MSP
domain might cause the mutant domain to change its substrate specificity. Also such
mutation produced striking differences in ER localization, thus implying that the VCS
may be involved as well. Additionally, because the methyl side chain of Alanine is
relatively small as compared to that isoleucine, the structural consequence of T46A or
T47A mutation may not disrupt the hydrophobic core as much as an isoleucine mutation
does.
Finally, evidences that the MSP domain of wt-VAPB interacts with EphA4 was also
presented. This binding can be disrupted either by the pathogenic T46I mutation or in the
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presence of FFAT containing peptide. In the co-crystal of ephA4 and ephrin-B2 binding,
four loops (A-C, D-E, G-H, and J-K) have been demonstrated to undergo substantial
movements. Interestingly, several residues such as E34 and K35 in the DE loop; 80C,
G85 and V86 in the GH loop; F126, T127, Q128, I131, G132, R134, L138 and N139 in
the JK loop of EphA4 have also been perturbed upon wt-VAPB binding, This thus
implies that the MSP domain might bind to the same interface as Epherin-B2. Indeed, it
has been demonstrated by Tsuda et al., 2008 that epherin-B2 can block binding of MSP
and EphA4. Together, these data suggest that the binding surface on MSP which interacts
with EphA4 and FFAT may largely overlap with each other.
In conclusion, through this study, we have shown that mutation/modification on
strategic positions may dramatically eliminate the ability of the mutant sequences to fold
into the stable and well-folded structures adopted by the wild type sequences. As a
consequence, the partially-folded or highly disordered mutants with many hydrophobic
side chains exposed can only be dissolved in salt-free water but not in buffers mimicking
the physiological condition. Additionally, we have also rationalize the previous
observations in vivo and strongly imply the interplay of the signaling networks associated
with Eph and FFAT-containing proteins may play a key role in ALS pathogenesis.
In future, it will be interesting to delineate the interaction of play between FFAT-
motif containing proteins, EphA4 and MSP domain in vivo studies. Although
crystallization trials have failed so far, continued efforts to screen using more diverse
crystallization conditions might yield favorable results. It is also interesting to note that
although the hanging drops consisted of EphA4 and VAPB MSP domain mixed in a 1:1
ratio at high concentration with homogenous purity, only EphA4 had aggregated into
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crystals. It is worth to diffract this free EphA4 crystal grown in the presence of the MSP
domain. In addition, we could also harness the information gathered form NMR titration
experiments to construct a model of the EphA4-MSP complex using HADDOCK.
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Chapter 4
Effects of Proline substitutions in VAPB (P56S)
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As mentioned, other than Pro-63 in the VCS of VAPA MSP domain, two other
prolines at position 13 and 97 were also substituted in wt-VAPB (Figure 19a). Here, the
substitutions of Gln-13, Ala-63 and Thr-97 to a Proline residue were investigated to see if
it would affect the structural characteristics of VAPB (P56S). To achieve this,
recombinant VAPB (Q13P, P56S); VAPB (P56S, A63P); VAPB (Q13P , T97P); VAPB
(Q13P , P56S, A63P, ) and VAPA (P56S) MSP domain (1-125) was cloned, expressed and
purified using a prokaryotic system under the native condition. Except for VAPA (P56S)
which was highly soluble in the buffer systems (5mM phosphate 1mM DTT pH6.5) we
used, all the other mutants were prone to aggregation at high concentration (~100uM) and
temperature. CD and NMR spectroscopy was utilized to study its structural properties.
4.1. Effects of Proline substitutions on the structural characteristics of VAPB
(P56S)
As shown in Figure 5a, at pH 6.5, the Far-UV CD spectroscopy of VAPB (P56S)
showed a spectrum with a prominent single negative band at ~215nm but no positive
signal at ~199nm. At this pH, the sample is heavily precipitated and light scattering
which results from these particles causes anomalies in the circular dichroism spectra
(Litman, 1972). Also no HSQC peaks could be detected at pH6.5. Henceforth we
suggested that the CD spectra of VAPB (P56S) at pH 6.5 was probably an artifact of
aggregated sample and hence was not used for comparison with the rest of the mutants.
In figure 19b, the Far-UV CD spectroscopy of VAPB (Q13P, P56S, A63P, T97P)
showed a spectrum which clearly resembles that of wt-VAPB with the maximal negative
signal at ~218 nm and positive signal at ~199 nm. The intensity of the positive signal at
~199 is also lower as compared to wt-VAPB. In contrast, the substitution of a single
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Proline in the VAPB (Q13P, P56S); VAPB (P56S, A63P) and VAPB (Q13P, T97P)
mutants showed a spectra which is similar to each other but are distinctly different from
wt-VAPB and VAPB (Q13P, P56S, A63P, T97P). This implies that probably all 3 prolines
are required to be introduced back into VAPB (P56S) in order to recover its native
structure. Nevertheless, as indicated by a reduced positive signal at ~199nm, this
restoration of native structure is incomplete and the protein may still be unfolded to some
degree.
NMR spectroscopy was also utilized to study the effect of Proline substitution on
the structural characteristics of P56S-VAPB. As seen in figure 20a-d, the mutants have a
HSQC spectrum characteristic of a well folded protein with a wide dispersion over the 1H
and 15N dimensions. Interestingly, many HSQC peaks of the mutants are also
superimposable to those of wt-VAPB, implying that the mutants might have a
conformational ensemble similar to that of wt-VAPB. The numbers of peaks in the HSQC
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spectrum of all the mutants were also greater than expected from the amino acid sequence
of the MSP domain.  In addition, obvious line-broadenings were also observed in all
spectra.
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4.2. Effects of Proline substitution on the stability of VAPB (P56S)
Next, the effect of temperature on the stability of all the different mutants was
explored. Strikingly, as shown in Figure 21a-d, the 1D spectrum showed drastic line
broadening and intensity dipped starting at 30°C for the mutants with a single Proline
substitution.  On the other hand, VAPB (Q13P, P56S, A63P, T97P) starts to aggregate
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only after 35°C and VAPA (P56S) at 40°C (figure 22). This indicates that although the
substitution of Proline residues into VAPB (P56S) makes it more stable and tolerable to
aggregation at high temperature, there are also certain other critical residues in VAPA
which are more crucial in maintaining stability.
4.3. Effects of Proline substitution on the binding ability of VAPB (P56S)
Since the introduction of additional Proline residues have prevented P56S from
abolishing the native state of VAPB MSP domain, it is interesting to see if it had restored
its ability to bind the FFAT motif containing Nir2 peptide as well. Hence the
thermodynamic parameters for the binding between the various Proline mutants and the
FFAT-containing motif of the Nir2 protein were measured by ITC (Figure 23). The VAPB
(Q13P, P56S, A63P, T97P) mutant is able to bind the FFAT-motif containing Nir2
peptide, with a dissociation constant (KD) of 1.75 µM.  Additionally, VAPB (P56S, A63P)
and VAPB (P56S, T97P) also bind but with weaker affinity at 4.27uM and 4.78uM
respectively. Strangely, although we have suggested that a single Proline addition to
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VAPB (P56S) might not restore the native state of wt-VAPB MSP domain as much as an
addition of 3 Proline residues would, VAPB (Q13P, P56S) binds with an affinity of
1.92uM which is comparable to that of  VAPB (Q13P, P56S, A63P, T97P).
4.4. Discussions, conclusion and future directions
The mis-sense mutation of Proline-56 to Serine in the MSP domain of VAPB
causes ALS8. In contrast, its isoform, VAPA is not significantly affected by the same
mutation. Last year, Nakamichi et al., (2010) had demonstrated that it was the existence
of Pro-63 that confers VAPA the resistance to the pathogenic Pro56Ser mutation.
Intuitively, they went on to investigate if the addition of Pro-63 has the same effect on
VAPB (P56S). However, they found that the localization of VAPB (P56S, A63P) was
similar to that of VAPB (P56S) and different from that of VAPA (P56S). They thus
suggested that another factor(s) other than Proline distribution in the VCS is required for
proper localization of VAPB.
Through the alignment of the different isoforms of VAPA and VAPB (figure 19a),
we realized that other than Pro-63 in the VCS of the MSP domain, two other prolines at
position 13 and 97 were also substituted in wt-VAPB. We have demonstrated that
although VAPB (P56S, A63P) has a native secondary and tertiary structure, it is still
thermodynamically unstable. As compared to VAPB (T46I) and VAPA (P56S) which
starts to precipitate at ~40°C, VAPB (P56S, A63P) precipitates at ~30°C as indicated by
the change of the up field peaks in the one-dimensional NMR proton spectra (figure 12,
21b and 22b). This significantly reduce stability, consequently caused the VAPB (P56S,
A63P) MSP domain to be prone to aggregation at high protein concentrations and
temperatures in vitro, which may become more severe in cellular environments resulting
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in improper localization as observed by Nakamichi et al., (2010). The effects are similar
for VAPB (Q13P, P56S) and VAPB (P56S, T97P). Interestingly, the addition of three
prolines in VAPB (Q13P, P56S, A63P, T97P) confers increased thermodynamic stability
to the mutant MSP mutant as compared to those which had one additional Proline.
Our study also demonstrated for the first time that the addition of Prolines to
VAPB (P56S) restored its ability to bind to FFAT-motif containing Nir2 peptide.
Intriguingly, while the VAPB (P56S, A63P) - and VAPB (P56S, T97P) - MSP domain has
a lower binding affinity to the FFAT-motif containing Nir2 peptide, VAPB (P56S, Q13P)
bind to the Nir2 peptide as tightly as the MSP domain of VAPB (Q13P, P56S, T97P).
Further studies have to be done to understand the underlying molecular mechanism.
Probably, we could use molecular simulation to model the consequences of the different
Proline mutants. Upon close examination of the HSQC of VAPB (P56S, Q13P), we also
noticed that the occurrence of repeating resonance peaks were significantly lesser. In
future, assignment of the HSQC peaks might also bring further insights.
In addition, it will be also interesting to investigate the localization of the Proline
mutants in yeast models. We could also study the thermodynamic stability and binding
ability of mutants which are systemically substituted to increase the identity of VAPB to
VAPA. It is hope that the results gathered might further provide valuable insights into
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